Jump­ing on an­ti-ag­ing band­wag­on, Y Com­bi­na­tor joins hunt for the $100B pill

An­ti-ag­ing up­starts have been pop­ping up across the biotech land­scape, with a slate of biotechs rac­ing to­wards a mar­ket op­por­tu­ni­ty worth un­told bil­lions to the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA